Gene discovery and validation for neurodegenerative diseases

Drug Discovery Today

Volumn 8, Issue 1, 2003, Pages 39-46

  Mathisen, Peter M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; DEGENERATIVE DISEASE; DRUG RESEARCH; GENETIC PROCEDURES; HUMAN; MULTIPLE SCLEROSIS; PARKINSON DISEASE; REVIEW; VALIDATION PROCESS;

EID: 0037248520     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359644602025400     Document Type: Review

References (96)

1. Foster W.R., Huber R.M. Current themes in microarray experimental design and analysis. Drug Discov. Today. 7:2002;290-292.
2. Augen J. The evolving role of information technology in the drug discovery process. Drug Discov. Today. 7:2002;315-323.
3. Palfreyman M.G. Human tissue in target identification and drug discovery. Drug Discov. Today. 7:2002;407-409.
4. Mielke K., Herdegen T. JNK and p38 stress kinases - degenerative effectors of signal-transduction-cascades in the nervous system. Prog. Neurobiol. 61:2000;45-60.
5. Tatton W.G., et al. Glyceraldehyde-3-phosphate dehydrogenase in neurodegeneration and apoptosis signaling. J. Neural Transm. Suppl. 60:2000;77-100.
6. Ko J., et al. p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J. Neurosci. 21:2001;6758-6771.
7. Lee M.S., et al. Neurotoxicicty induces cleavage of p35 top25 by calpain. Nature. 405:2000;360-394.
8. Chae T., et al. Mice lacking p35, a neuronal specific activator of Cdk5, display cortical lamination defects, seizures, and adult lethality. Neuron. 18:1997;26-42.
9. Ohshima T., et al. Targeted disruption of the cyclin-dependent kinase 5 gene results in abnormal corticogenesis, neuronal pathology and perinatal death. Proc. Natl. Acad. Sci. U. S. A. 93:1996;11173-11178.
10. Bibb J.A., et al. Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signaling in neurons. Nature. 402:1999;669-671.
11. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 399:1999;A23-A31.
12. Chapman P.F., et al. Genes, models, and Alzheimer's disease. Trends Genet. 17:2001;254-261.
13. Dingwall C. Spotlight on BACE: the secretases as targets for treatment in Alzheimer disease. J. Clin. Invest. 108:2001;1243-1246.
14. Esler P.W., Wolfe M.S. A portrait of Alzheimer secretases - new features and familiar faces. Science. 293:2001;1449-1454.
15. Vassar R., Citron M. Aβ-generating enzymes: recent advances in β- and γ-secretase research. Neuron. 27:2000;419-422.
16. Trojanowski J.Q. Neuropathological verisimilitude in animal models of Alzheimer's disease: key to elucidating neurodegenerative pathways and identifying new targets for drug discovery. Am. J. Pathol. 160:2002;409-411.
17. Bennett B.D., et al. A furin-like convertase mediates propeptide cleavage of BACE, the Alzheimer's β-secretase. J. Biol. Chem. 275:2000;37712-37717.
18. Creemers J.M.W., et al. Processing of β-secretase by furin and other members of the proprotein convertase family. J. Biol. Chem. 276:2000;4211-4217.
19. Benjannet S., et al. Post-translational processing of β-secretase (β-amyloid-converting enzyme) and its ectodomain shedding. J. Biol. Chem. 276:2001;10879-10887.
20. Hardy J., Isreal A. In search of γ-secretase. Nature. 398:1999;466-467.
21. Dovey H.F., et al. Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain. J. Neurochem. 76:2001;173-181.
22. Selkoe D.J. Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98:2001;11039-11041.
23. Hartmann D., et al. Implications of APP secretases in Notch signaling. J. Mol. Neurosci. 17:2001;171-181.
24. Iwata N., et al. Metabolic regulation of brain Aβ by neprilysin. Science. 292:2001;1550-1552.
25. Russo C., et al. Signal transduction through tyrosine-phosphorylated C-terminal fragments of amyloid precursor protein via an enhanced interaction with Shc/Grb2 adaptor proteins in reactive astrocytes of Alzheimer disease brain. J. Biol. Chem. 277:2002;35282-35288.
26. Schenk D.B., et al. β peptide immunization: a possible new treatment for Alzheimer disease. Arch. Neurol. 57:2000;934-936.
27. Shenk D., et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:1999;173-177.
28. Janus C., et al. A β peptide immunization reduces behavioural impairment and plagues in a model of Alzheimer's disease. Nature. 408:2000;979-982.
29. Morgan D., et al. A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:2000;982-985.
30. Demattos R.B., et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 98:2001;8850-8855.
31. Bard F., et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat. Med. 6:2000;916-919.
32. Russo C., et al. Molecular aspects of neurodegeneration in Alzheimer's disease. Funct. Neurol. 17:2002;65-70.
33. Mudher A., Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci. 25:2002;22-26.
34. Tanemura K., et al. Formation of filamentous tau aggregations in transgenic mice expressing V337M human tau. Neurobiol. Dis. 8:2001;1036-1045.
35. Ho L., et al. Gene expression profiling of the tau mutant (P301L) transgenic mouse brain. Neurosci. Lett. 310:2001;1-4.
36. Pei J.J., et al. Accumulation of cyclin-dependent kinase 5 (Cdk5) in neurons with early stages of Alzheimer's disease neurofibrillary degeneration. Brain Res. 797:1998;267-277.
37. Lee K.Y., et al. Elevated neuronal Cdc2-like kinase activity in the Alzheimer disease brain. Neurosci. Res. 34:1999;21-29.
38. Ahlijanian M.K., et al. Hyperphosphorylated Tau and neurofilamennt and cytoskeletal disruptions in mice overexpressing human p25, an activator of Cdk5. Proc. Natl. Acad. Sci. U. S. A. 97:2000;2910-2915.
39. Pansinetti G.M. Use of cDNA microarray in the search for molecular markers involved in the onset of Alzheimer's disease dementia. J. Neurosci. Res. 65:2001;471-476.
40. Pansinetti G.M., Ho L. From cDNA microarrays to high-throughput proteomics. Implications in the search for preventive initiatives to slow the clinical progression of Alzheimer's disease dementia. Restor. Neurol. Neurosci. 18:2001;137-142.
41. Scott H.L., et al. Aberrant expression of the glutamate transporter excitatory amino acid transporter 1 (EAAT1) in Alzheimer's disease. J. Neurosci. 22:2002;1-5.
42. Hashimoto Y., et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ Proc. Natl. Acad. Sci. U. S. A. 98:2001;6336-6341.
43. Tuohy V.K., et al. The epitope spreading cascade during progression of experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol. Rev. 164:1998;93-100.
44. Tuohy V.K., et al. Modulation of the IL-10/IL-12 cytokine circuit by interferon-β inhibits of the development of epitope spreading and disease progression of murine autoimmune encephalomyelitis. J. Neuroimmunol. 111:2000;55-63.
45. Wiendl H., Hohfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs. 16:2002;183-200.
46. Sorensen T.L., et al. Multiple sclerosis: a study of CXCL120 and CXCR3 co-localization in the inflamed central nervous system. J. Neuroimmunol. 127:2002;59-68.
47. van der Lann L.J.W., et al. Beneficial effect of modified peptide inhibitor of α4 integrin on experimental allergic encephalomyelitis in Lewis rats. J. Neurosci. Res. 67:2002;191-199.
48. Muraro P.A., et al. VLA-4/CD49d downregulated on primed T lymphocytes during interferon-β therapy in multiple sclerosis. J. Neuroimmunol. 111:2000;186-194.
49. Theien B.E., et al. Discordant effects of anti-VLA-4 treatment before and after onset of relapsing experimental autoimmune encephalomyelitis. J. Clin. Invest. 107:2001;995-1006.
50. + channel, IKCa1: a potential immunosuppressant. Proc. Natl. Acad. Sci. U. S. A. 97:2000;8151-8156.
51. + channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation. J. Immunol. 166:2001;936-944.
52. Iwata S., et al. CD26/dipeptidyl peptidase IV differentially regulates the chemotaxis of T cells and monocytes toward RANTES: possible mechanism for the switch from innate to acquired immune response. Int. Immunol. 11:1999;417-423.
53. + T cell clones. J. Neuroimmunol. 87:1998;203-209.
54. Ramanathan M., et al. In vivo expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. J. Neuroimmunol. 116:2001;213-219.
55. Whitney L.W., et al. Analysis of gene expression in multiple sclerosis lesions using cDNA microarrays. Ann. Neurol. 46:1999;425-428.
56. Funk C., Chen X.-S. 5-Lipoxygeenase and leukotrienes. Transgenic mouse and nuclear targeting studies. Am. J. Respir. Crit. Care Med. 161:2000;S120-S124.
57. Chabas D., et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science. 294:2001;1731-1735.
58. Lock C., et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8:2002;500-508.
59. Steinman L. Assessment of animal models for MS and demyelinating disease in the design of rational therapy. Neuron. 24:1999;511-514.
60. Chang A., et al. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N. Engl. J. Med. 346:2002;165-173.
61. Pender M.P. Genetically determined failure of activation-induced apoptosis of autoreactive T cells as a cause of multiple sclerosis. Lancet. 351:1998;978-981.
62. Schapira A.H. Neuroprotection and dopamine agonists. Neurology. 58:2002;S9-S18.
63. Hartmann A., et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 97:2000;2875-2880.
64. Viswanath V., et al. Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J. Neurosci. 21:2001;9519-9528.
65. Sayre L.M., et al. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med. Chem. 8:2001;721-738.
66. Kikuchi A., et al. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol. Dis. 9:2002;244-248.
67. Maruyama W., et al. The anti-parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neural Transm. 109:2002;467-481.
68. Du Y., et al. Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 98:2001;14669-14674.
69. Le W., et al. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J. Neurosci. 21:2001;8447-8455.
70. Youdim M.B., et al. Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression. Adv. Neurol. 86:2001;115-124.
71. Mouradian M.M. Recent advances in the genetics and pathogenesis of Parkinson's disease. Neurology. 58:2002;179-185.
72. Junn E., Mouradian M.M. Human α-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 320:2002;146-150.
73. Kruger R., et al. Parkinson's disease: one biochemical pathway to fit all genes? Trends Mol. Med. 8:2002;236-240.
74. Chung K.K., et al. The role of the ubiquitin-proteasomal pathway in Parkinson's disease and other neurodegenerative disorders. Trends Neurosci. 24:(Suppl.):2001;S7-S14.
75. Grunblatt E., et al. Gene expression analysis in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice model of Parkinson's disease using cDNA microarray: effect of R-apomorphine. J. Neurochem. 78:2001;1-12.
76. Rosen D.R., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 362:1993;59-62.
77. Gurney M.E., et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 264:1994;1772-1775.
78. Wong P.C., et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 14:1995;1105-1116.
79. Cluskey S., Ramsden D.B. Mechanisms of neurodegeneration in amyotrophic lateral sclerosis. J. Clin. Pathol. 54:2001;386-392.
80. Shaw C.E., et al. Progress in the pathogenesis of amyotrophic lateral sclerosis. Curr. Neurol. Neurosci. Rep. 1:2001;69-77.
81. Rothstein J.D., et al. Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis. Ann. Neurol. 28:1990;18-25.
82. Bensimon G., et al. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J. Neurol. 249:2002;609-615.
83. Jackson M., et al. Polymorphisms in the glutamate transporter gene EAAT2 in European ALS patients. J. Neurol. 246:1999;1140-1144.
84. Trotti D., et al. Amyotrophic lateral sclerosis-linked glutatmate transporter mutant has impaired glutamate clearance capacity. J. Biol. Chem. 276:2001;576-582.
85. Bristol L.A., Rothstein J.D. Glutamate transporter gene expression in amyotrophic lateral sclerosis motor cortex. Ann. Neurol. 39:1996;676-679.
86. Shaw P.J., Eggett C.J. Molecular factors underlying selective vulnerability of motor neurons to neurodegeneration in amyotrophic lateral sclerosis. J. Neurol. 247:(Suppl. 1):2000;17-27.
87. Comi G.P., et al. Cytochrome c oxidase subunit I microdeletion in a patient with motor neuron disease. Ann. Neurol. 43:1998;110-116.
88. Borthwick G.M., et al. Mitochondrial enzyme activity in amyotrophic lateral sclerosis: implications for the role of mitochondria in neuronal cell death. Ann. Neurol. 46:1999;787-790.
89. Strong M.J. Neurofilament metabolism in sporadic amyotrophic lateral sclerosis. J. Neurol. Sci. 169:1999;170-177.
90. Beaulieu J.M., et al. Late onset death of motor neurons in mice overexpressing wild-type peripherin. J. Cell Biol. 147:1999;531-544.
91. Ikeda K., et al. Coadministration of interleukin-6 (IL-6) and soluble IL-6 receptor delays progression of wobbler mouse neuron disease. Brain Res. 726:1996;91-97.
92. Kurek J.B., et al. LIF (AM424), a promising growth factor for the treatment of ALS. J. Neurol. Sci. 160:(Suppl. 1):1998;6-13.
93. Askanas V. Neurotrophic factors and amyotrophic lateral sclerosis. Adv. Neurol. 68:1995;241-244.
94. Apfel S.C. Neurotrophic factor therapy - prospects and problems. Clin. Chem. Lab. Med. 39:2001;351-355.
95. Alvarez A., et al. Inhibition of tau phosphorylating protein kinase cdk5 prevents β-amyloid-induced neuronal death. FEBS Lett. 459:1999;421-426.
96. Nguyen M.D., et al. Deregulation of Cdk5 in a mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron. 30:2001;135-147.